King's College London

Research portal

The role of the interleukin (IL)-6/IL-6 receptor axis in cancer

Research output: Contribution to journalReview article

Standard

The role of the interleukin (IL)-6/IL-6 receptor axis in cancer. / Taher, Mustafa Yassin; Davies, David Marc; Maher, John.

In: Biochemical Society Transactions, Vol. 46, No. 6, 22.11.2018, p. 1449-1462.

Research output: Contribution to journalReview article

Harvard

Taher, MY, Davies, DM & Maher, J 2018, 'The role of the interleukin (IL)-6/IL-6 receptor axis in cancer', Biochemical Society Transactions, vol. 46, no. 6, pp. 1449-1462. https://doi.org/10.1042/BST20180136

APA

Taher, M. Y., Davies, D. M., & Maher, J. (2018). The role of the interleukin (IL)-6/IL-6 receptor axis in cancer. Biochemical Society Transactions, 46(6), 1449-1462. https://doi.org/10.1042/BST20180136

Vancouver

Taher MY, Davies DM, Maher J. The role of the interleukin (IL)-6/IL-6 receptor axis in cancer. Biochemical Society Transactions. 2018 Nov 22;46(6):1449-1462. https://doi.org/10.1042/BST20180136

Author

Taher, Mustafa Yassin ; Davies, David Marc ; Maher, John. / The role of the interleukin (IL)-6/IL-6 receptor axis in cancer. In: Biochemical Society Transactions. 2018 ; Vol. 46, No. 6. pp. 1449-1462.

Bibtex Download

@article{0e08a57515e94164a8014590e80813a7,
title = "The role of the interleukin (IL)-6/IL-6 receptor axis in cancer",
abstract = "Interleukin-6 (IL-6) is a pleiotropic cytokine that activates a classic signalling pathway upon binding to its membrane-bound receptor (IL-6R). Alternatively, IL-6 may ‘trans-signal’ in a manner that is facilitated by its binding to a soluble derivative of the IL-6 receptor (sIL-6R). Resultant signal transduction is, respectively, driven by the association of IL-6/IL-6R or IL-6/sIL-6R complex with the membrane-associated signal transducer, gp130 (Glycoprotein 130). Distinct JAK (Janus tyrosine kinase)/STAT (signal transducers and activators of transcription) and other signalling pathways are activated as a consequence. Of translational relevance, overexpression of IL-6 has been documented in several neoplastic disorders, including but not limited to colorectal, ovarian and breast cancer and several haematological malignancies. This review attempts to summarise our current understanding of the role of IL-6 in cancer development. In short, these studies have shown important roles for IL-6 signalling in tumour cell growth and survival, angiogenesis, immunomodulation of the tumour microenvironment, stromal cell activation, and ultimate disease progression. Given this background, we also consider the potential for therapeutic targeting of this system in cancer.",
author = "Taher, {Mustafa Yassin} and Davies, {David Marc} and John Maher",
year = "2018",
month = "11",
day = "22",
doi = "10.1042/BST20180136",
language = "English",
volume = "46",
pages = "1449--1462",
journal = "Biochemical Society Transactions",
issn = "0300-5127",
publisher = "Portland Press Ltd.",
number = "6",

}

RIS (suitable for import to EndNote) Download

TY - JOUR

T1 - The role of the interleukin (IL)-6/IL-6 receptor axis in cancer

AU - Taher, Mustafa Yassin

AU - Davies, David Marc

AU - Maher, John

PY - 2018/11/22

Y1 - 2018/11/22

N2 - Interleukin-6 (IL-6) is a pleiotropic cytokine that activates a classic signalling pathway upon binding to its membrane-bound receptor (IL-6R). Alternatively, IL-6 may ‘trans-signal’ in a manner that is facilitated by its binding to a soluble derivative of the IL-6 receptor (sIL-6R). Resultant signal transduction is, respectively, driven by the association of IL-6/IL-6R or IL-6/sIL-6R complex with the membrane-associated signal transducer, gp130 (Glycoprotein 130). Distinct JAK (Janus tyrosine kinase)/STAT (signal transducers and activators of transcription) and other signalling pathways are activated as a consequence. Of translational relevance, overexpression of IL-6 has been documented in several neoplastic disorders, including but not limited to colorectal, ovarian and breast cancer and several haematological malignancies. This review attempts to summarise our current understanding of the role of IL-6 in cancer development. In short, these studies have shown important roles for IL-6 signalling in tumour cell growth and survival, angiogenesis, immunomodulation of the tumour microenvironment, stromal cell activation, and ultimate disease progression. Given this background, we also consider the potential for therapeutic targeting of this system in cancer.

AB - Interleukin-6 (IL-6) is a pleiotropic cytokine that activates a classic signalling pathway upon binding to its membrane-bound receptor (IL-6R). Alternatively, IL-6 may ‘trans-signal’ in a manner that is facilitated by its binding to a soluble derivative of the IL-6 receptor (sIL-6R). Resultant signal transduction is, respectively, driven by the association of IL-6/IL-6R or IL-6/sIL-6R complex with the membrane-associated signal transducer, gp130 (Glycoprotein 130). Distinct JAK (Janus tyrosine kinase)/STAT (signal transducers and activators of transcription) and other signalling pathways are activated as a consequence. Of translational relevance, overexpression of IL-6 has been documented in several neoplastic disorders, including but not limited to colorectal, ovarian and breast cancer and several haematological malignancies. This review attempts to summarise our current understanding of the role of IL-6 in cancer development. In short, these studies have shown important roles for IL-6 signalling in tumour cell growth and survival, angiogenesis, immunomodulation of the tumour microenvironment, stromal cell activation, and ultimate disease progression. Given this background, we also consider the potential for therapeutic targeting of this system in cancer.

UR - http://www.scopus.com/inward/record.url?scp=85058503446&partnerID=8YFLogxK

U2 - 10.1042/BST20180136

DO - 10.1042/BST20180136

M3 - Review article

C2 - 30467123

AN - SCOPUS:85058503446

VL - 46

SP - 1449

EP - 1462

JO - Biochemical Society Transactions

JF - Biochemical Society Transactions

SN - 0300-5127

IS - 6

ER -

View graph of relations

© 2018 King's College London | Strand | London WC2R 2LS | England | United Kingdom | Tel +44 (0)20 7836 5454